Drug Trial Radar · NCT05405595
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
186
Planned (sponsor's estimate)
Start
Jun 15, 2022
Primary completion
Jun 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Adagene IncIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jun 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2, open-label, dose escalation, dose expansion and dose optimization study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic solid tumors. The study drug ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. Pembrolizumab is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody).
Conditions
- Advanced/Metastatic Solid Tumors
Interventions
ADG126Drug
ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4.
Pembrolizumab (KEYTRUDA®)Drug
Pembrolizumab (KEYTRUDA®) is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody).
Standard of Care (Trifluridine/Tipiracil-Bevacizumab)Drug
The standard of care therapies will include Trifluridine/Tipiracil-Bevacizumab, approved for treating metastatic colorectal cancer (CRC)and various solid tumors.
Standard of care (Fruquintinib)Drug
The standard of care therapy, Fruquintinib, is approved for treating metastatic colorectal cancer (CRC) and various solid tumors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) and RP2D for ADG126 in combination with pembrolizumab.Time frame: 9 months
- the safety and tolerability of ADG126 at escalating dose level in combination with pembrolizumab in adults with advanced metastatic solid tumorsTime frame: 9 months
- Access the preliminary antitumor activity of ADG126-pembrolizumab combination regimensTime frame: 9 months
- Maximum tolerated dose (MTD) and/or RP2D for ADG126 with Trifluridine/Tipiracil-BevacizumabTime frame: 6 months
- Access the preliminary antitumor activity of ADG126 with Pembrolizumab in combination standard of careTime frame: 6 months
- Access and characterize the optimal dose based on safety and efficacy parametersTime frame: 9 months
Locations
21 sites in 3 countries. Site status is shown where the registry gives one.
Honor Health Research Institute
Scottsdale, Arizona · Recruiting
City of Hope National Medical Center
Duarte, California · Recruiting
City of Hope Orange County
Irvine, California · Recruiting
Florida cancer specialist/Sarah Cannon Research Institute
Sarasota, Florida · Active not recruiting
The Cleveland Clinic
Cleveland, Ohio · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
SunYat-Sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Hong Kong Humanity & Health Clinical Trial Center
Hong Kong, Hong Kong, China · Recruiting
Prince of Wales Hospital
Hong Kong, Hong Kong, China · Recruiting
Keimyung University Dongsan Hospital
Daegu, South Korea · Terminated
Seoul National University Hospital
Seoul, South Korea · Recruiting
KangBuk Samsung Hospital
Seoul, South Korea · Terminated
Asan Medical Center
Seoul, South Korea · Recruiting
Severance Hospital Yonsei University Health System
Seoul, South Korea · Recruiting
Dong -A University Hospital
Seogu, Busan Gwangyeogsi, South Korea · Terminated
CHA Bundang Medical Center, CHA university
Seongnam, Gyeonggido, South Korea · Recruiting
The Catholic University of Korea Street. Vincent Hospital
Suwon, Gyeonggido, South Korea · Terminated
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea · Recruiting
Samsung Medical Center
Seoul, Seoul Teugbyeolsi, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.